statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and...

New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera in Breast Cancer

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on...

Natera to Report its First Quarter 2024 Results on May 9

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test. This comes at a critical time for the...

Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200...

Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney...

Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasing the ability of the Prospera...

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera Heart dd-cfDNA Test for Heart Transplant Recipients

Natera (NASDAQ:NTRA - Get Free Report) was upgraded by equities research analysts at Sanford C. Bernstein from a "market perform" rating to an "outperform" rating in a report issued on Friday...

Natera (NASDAQ:NTRA) Raised to "Outperform" at Sanford C. Bernstein

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress...

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

Natera, Inc. (NASDAQ:NTRA - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q4 2024 earnings per share (EPS) estimates for shares of Natera in a research note issued on...

Q4 2024 EPS Estimates for Natera, Inc. (NASDAQ:NTRA) Decreased by Analyst

Insider Sell: CFO Michael Brophy Sells Shares of Natera Inc (NTRA)

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.

Watchers	1,704
52-Wk Low	$36.90
52-Wk High	$98.82

Volume	317,445.00
52-Wk High	$98.82
52-Wk Low	$36.90

NTRA Natera Inc

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community